LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) will announce its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
LENZ Therapeutics Stock Performance
Shares of LENZ stock opened at $27.93 on Monday. LENZ Therapeutics has a 12-month low of $14.07 and a 12-month high of $31.00. The company has a 50 day moving average of $24.03 and a 200-day moving average of $20.74.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on LENZ Therapeutics
LENZ Therapeutics Company Profile
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Stories
- Five stocks we like better than LENZ Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Why Gold Prices Could Surge to $3,000: Key Drivers for Bulls
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Stocks Under $20 With Strong-Buy Ratings
- The Basics of Support and Resistance
- November’s Small-Cap Treasures: 3 Stocks Poised for Growth
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.